Persistent Atrial Fibrillation
Conditions
Interventions
experimental group:take Entresto
control group:Blank control
Sponsors
The First Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
19 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years old, male or female; 2. Physical condition allows oral medication; 3. Patients confirmed by 24h ambulatory electrocardiogram and clinically diagnosed as persistent atrial fibrillation who have undergone transcatheter cardiac electrophysiological examination and ablation (successfully converted to sinus rhythm confirmed by electrocardiogram within 24h after operation); 4. Patients who understand the purpose of the trial and agree to all research steps, voluntarily sign the informed consent form, and are willing to follow up the study.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Have suffered from acute coronary syndrome (including myocardial infarction), acute stroke, cardiac surgery, other major cardiovascular surgery or emergency percutaneous coronary intervention within 3 months before enrollment; 3. Complicated with heart failure:have had a clinical basis in line with the diagnosis of heart failure, the clinical diagnosis is heart failure, or transthoracic color Doppler echocardiography indicates that the left ventricular ejection fraction is less than 50%; 4. Patients with acute infectious diseases, important organ injuries, malignant tumors or life expectancy less than 1 year; 5. Severe liver and kidney dysfunction; 6. The average blood pressure measured three times after operation is lower than 100/60mm Hg (1mmhg=0.133 kPa); 7. Abnormal coagulation mechanism and immune function; 8. The subjects are currently participating in another clinical study of drugs or devices whose primary endpoint has not been completed; 9. The researcher believes that the subject is unable to follow the requirements of the study plan or believes that the subject is not suitable to participate in the study for any reason; 10. People who are allergic to the active ingredients or any excipients of sacubatrovalsartan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sinus rhythm maintenance rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rates of all-cause death or rehospitalization for cardiovascular causes;Incidence of major adverse cardiovascular events;Changes of cardiac structural and functional indexes; | — |
Countries
China
Contacts
Public ContactChen Yequn
The First Affiliated Hospital of Shantou University Medical College
Outcome results
None listed